Biopharmaceutical Manufacturing, Upstream, Downstream …
3 days ago · News on the biopharmaceutical manufacturing industry, focusing on biologics, technology, upstream/downstream processing, cell culture and regulations
Bio developments - News - Biopharma-Reporter.com
Dec 17, 2024 · News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
How will the Biosecure Act impact the pharma industry?
Oct 8, 2024 · But what does the Act mean for the biotech and pharma industry and how can companies best prepare for any impacts on future business? The Biosecure Act was first …
Bio developments - biopharma-reporter.com
Dec 10, 2024 · The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA approval in adults aged 18 to 59 who are at an …
Trends in biosimilars: Regulatory approvals in 2024
Jul 24, 2024 · The biosimilars market is rapidly growing as global demand for biosimilars continues to grow. The global biosimilar market is estimated to reach a size of $43.8 billion by …
BioPharmaReporter gets a new look
Nov 26, 2024 · We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t change, but we’ve tweaked the look and feel …
Trends - biopharma-reporter.com
Nov 14, 2024 · News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Three Indian CDMOs ready to seize the BIOSECURE Act opportunity
Jun 6, 2024 · Spearheading this effort is the BIOSECURE Act, a bipartisan initiative gaining traction in Congress with the potential to reshape America's defense against pandemics and …
Pharma and biopharma outsourcing strategies need to use an …
Oct 26, 2022 · But a new CPhI report on 'The Future of Outsourcing' advises against this approach. “Traditionally, outsourcing strategies were designed to help secure next stage …
EY: Signs biopharma industry ready to return to the big …
Jan 12, 2023 · EY research found that, for the first 11 months of 2022, biopharma M&A value dropped 42% compared with 2021. “Alliances remain a significant focus for biopharma and …